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Abstract The auxiliary regulatory protein Vpr of HIV-1 pos-
sesses several biological activities which are believed to facilitate
HIV-1 replication and pathogenesis. In this report, experimental
evidence suggests a novel biological activity of Vpr: facilitation
of the turnover of Vpr mutants bearing the L64P mutation. This
novel activity of Vpr was shared by Vpr molecules from di¡er-
ent subtypes of HIV-1. Co-expression of the wild type Vpr with
the VprW54A/L64P mutant resulted in normal synthesis of the
mutant mRNA but enhanced ubiquitination and turnover of the
mutant protein. These results suggest that Vpr may interact
with the ubiquitin/proteasome pathway to regulate the stability
of viral or cellular proteins.
- 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
HIV-1 Vpr is a 96-amino acid, 14-kDa auxiliary regulatory
protein synthesized in the late phase of the HIV-1 life cycle
and packaged into the virion through interaction with Gag
[1^3]. Potential functions of Vpr during the HIV-1 life cycle
include facilitation of the nuclear transport of the HIV-1 pre-
integration complex [4], transcriptional activation [5^9], and
cell cycle arrest [10^12]. Vpr has also been shown to induce
apoptosis in di¡erent cell types and transgenic mice [13^20].
In groups of so-called long-term non-progressors, mutations
in Vpr are found to reduce or abolish the pro-apoptotic po-
tential of Vpr [17,21], suggesting that the pro-apoptotic activ-
ity of Vpr may contribute to the pathogenesis of AIDS. Cur-
rently, it remains unclear which of the Vpr activities is most
important for Vpr function during HIV-1 replication in vivo,
and whether there is a common biochemical mechanism
underlying some of the Vpr activities.
The function of Vpr appears to be most critical for HIV-1
replication in macrophages [22]. This is proposed to be due to
the requirement for the active nuclear transport function of
Vpr since macrophages do not have nuclear division [4]. As
nuclear transport function has also been assigned to the HIV-
1 integrase [23] and the MA component of Gag [24], it re-
mains possible that Vpr has an as yet unde¢ned unique mech-
anism of function for HIV-1 replication under in vivo condi-
tions. Under most in vitro conditions the existence of the Vpr
gene enhances HIV-1 replication only modestly and therefore
the mechanism of Vpr function during the HIV-1 life cycle has
been di⁄cult to discern. We recently reported that a single
L64P mutation of Vpr causes a profound enhancement of
the pro-apoptotic potential of Vpr [25]. In this study, co-ex-
pression of the wild type Vpr with L64P-containing Vpr mu-
tants is shown to severely reduce the protein level of the Vpr
mutants. This e¡ect is correlated with an enhanced ubiquiti-
nation and a faster rate of turnover of the Vpr mutants in the
presence of the wild type Vpr, and not due to e¡ects on the
mRNA level. This study suggests a novel biological activity of
Vpr which may facilitate the identi¢cation of a unique func-
tional mechanism for Vpr.
2. Materials and methods
2.1. Cell culture, transfection, and Western blots
293 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
supplemented with 10% fetal bovine serum and penicillin/streptomy-
cin, and transfected with Lipofectamine 2000 (Invitrogen) under con-
ditions previously described [25]. For analysis of Vpr dimerization in
vivo, 293 cells transfected for 2 days were cross-linked in vivo by
incubation with 5 mM of DSS (Pierce) for 30 min before lysis of
the cells for Western blot. HeLa cells were transfected with the Poly-
fect reagent (Qiagen) under recommended conditions. Brie£y, HeLa
cells were plated the day before transfection at 1.5U105 cells/well
density. The medium was replaced with fresh medium before trans-
fection. DNA precipitation was performed with 0.8 Wg of DNA and
6 Wl of the Polyfect reagent in a total volume of 50 Wl at room temper-
ature for 5^10 min. The DNA precipitates were added to cells and the
cells incubated in a CO2 incubator for 2 days before lysis for Western
blot analysis. Conditions for Vpr Western blots and analysis of apo-
ptotic DNA ladders were described before [25].
2.2. Analysis of ubiquitination
293 cells were co-transfected with 0.5 Wg of the pCMV-(HA-Ub)8
plasmid [26], and 0.75 Wg each of pFSZ3-F-W54A/L64P and pFSZ3-
Vpr. Two days after transfection, cells were treated with 50 WM of the
proteasome inhibitor MG132 (Sigma) for 2 h, and then lysed with the
immunoprecipitation bu¡er containing 50 mM Tris^HCl (pH 7.5), 1%
Triton X-100, 0.5 M NaCl, 0.5 mM dithiothreitol (DTT), and the
complete protease inhibitor cocktail (Roche). Cell lysates were immu-
noprecipitated with the Flag M2 antibody (Sigma), and the immuno-
precipitates were examined by Western blot with the Flag antibody or
the HA antibody [27].
2.3. Subcellular fractionation
Transfected 293 cells were harvested and incubated with a hypo-
tonic bu¡er (20 mM HEPES, pH 7.5, 10 mM KCl, 2 mM MgCl2,
0.5 mM DTT and 0.2 mM phenylmethylsulfonyl £uoride) for 5 min
on ice. After passing through a 27G needle 10 times, cells were cen-
trifuged for 3 min at 600Ug to separate the cytoplasmic fraction from
the nuclear pellet. The nuclear pellet was washed once with the hypo-
tonic bu¡er containing 20% glycerol. For Western blots, the cytoplas-
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mic fraction and the nuclear pellet were directly mixed with an sodium
dodecyl sulfate (SDS) sample loading bu¡er. For radiolabeled cells,
the nuclear pellet was extracted with the immunoprecipitation bu¡er
for 30 min at 4‡C. Both the cytoplasmic and the nuclear fractions
were immunoprecipitated with the Flag antibody and analyzed.
2.4. DNA cloning
Expression constructs for Vpr, VprL64P, VprL22A, VprE29A,
VprW54A and VprI61A/L64P were described before [25]. New double
point mutants of Vpr used for this study, including L22A/L64P,
E29A/L64P and W54A/L64P, were constructed by replacing the Bam-
HI/EcoRI restriction fragment of pFSZ3-VprL64P [25] with the cor-
responding fragment from the expression constructs for VprL22A,
VprE29A, and VprW54A, respectively. For expression of N-termi-
nally Flag-tagged Vpr proteins, the wild type or mutant Vpr genes
were polymerase chain reaction (PCR)-ampli¢ed with primer 1 ACA-
TGCGGATCCATGGCAGACTACAAGGACGACGACGACAAG-
GGGATGGAACAAGCCCCAGAAGACC and primer 2 ACATCA-
CTCGAGCTAGGATTTACTGGCTCCATTTCTTGTTCTCC. The
PCR DNA was digested with BamHI/SalI and cloned into the Bam-
HI/SalI sites of the pFSZ3 vector [25].
2.5. Reverse transcription (RT) PCR
Experimental conditions were modi¢ed from previous studies [28].
Brie£y, 293 cells in a six-well plate were co-transfected with 2 Wg each
of pFSZ3-F-Vpr and pFSZ3-W54A, or pFSZ3-F-Vpr and pFSZ3-
W54A/L64P [25]. mRNA was puri¢ed from the transfected cells using
the mRNA mini-prep kit (Amersham/Pharmacia), and precipitated
with ethanol. The puri¢ed mRNA (0.25 Wg) was used for RT reactions
in the presence or absence of the reverse transcriptase under previous
conditions [28] using primer 3 (GCTTCATTCTTAAGCTCCTC).
The RT products were serially diluted and used for PCR reactions
with primer 3 and primer 4 (GACTAGCGGAGGCTAGAAGGAG).
Sequences for both primer 3 and primer 4 were derived from the HIV-
1 genomic clone 89.6 (GenBank accession number U39362). PCR
reactions were performed for 21 cycles with 2 min annealing at
55‡C and 2 min extension at 68‡C. PCR products were subjected to
polyacrylamide gel (6%) electrophoresis (PAGE) followed by staining
with Vistra Green (Amersham), and quanti¢ed by £uorescence-image
analysis (Storm 840, Molecular Dynamics).
2.6. Pulse-chase protein labeling with [35S]methionine
293 cells in 12-well plates were transfected with pFSZ3-F-W54A/
L64P and pFSZ3-W54A/L64P, or pFSZ3-F-W54A/L64P and pFSZ3-
Vpr. Forty hours later, transfected cells were pre-incubated with me-
thionine-free medium (Invitrogen) for 30 min, and labeled for 30 min
with 0.3 ml of methionine-free medium containing 0.25 mCi
[35S]methionine/ml of Redivue Protein Labeling Mix (Amersham)
and 10% fetal bovine serum. Labeled cells were washed and then
incubated with regular medium. At various time points of the incu-
bation, cells were lysed with 0.4 ml of the immunoprecipitation bu¡er
used for ubiquitination analysis. The lysates were immunoprecipitated
with the Flag antibody and analyzed by SDS^PAGE followed by
phosphor-image analysis (Storm 840, Molecular Dynamics). For in-
hibition studies, transfected cells were labeled as described above and
then treated with 50 WM of MG132 for additional 45 min before lysis
of the cells for analysis of Vpr expression. For subcellular fractiona-
tion studies, cells treated as described above were washed and incu-
bated with the regular medium for additional 40 min to allow nuclear
migration of the newly labeled proteins. Cytoplasmic and nuclear
fractions were prepared as described above.
3. Results
3.1. The wild type Vpr inhibits VprL64P-induced apoptosis
Based on nuclear magnetic resonance (NMR) studies [29],
Vpr has three helical domains and two £exible terminal
domains (Fig. 1A). During our previous studies [25], we in-
troduced point mutations into the various structural domains
of Vpr to facilitate analysis of Vpr functions. After DNA
transfection into 293 cells, small molecular weight cellular
DNA, which is present only in apoptotic cells, was isolated
and analyzed for the existence of a DNA ladder of 200-bp
increments, which is the de¢ning feature of apoptosis. One
of the mutants, VprL64P (Fig. 1B, lane 3), has a dramati-
cally enhanced pro-apoptotic activity compared to the wild
type Vpr (lane 2). We subsequently examined the e¡ect of
Fig. 1. Inhibition of VprL64P-induced apoptosis by the wild type
Vpr. A: Amino acid sequence of the Vpr N-terminal region, with
the three helical regions underlined [29]. Leu64 is indicated by a
dot. B: Inhibition of VprL64P-induced apoptosis by the wild type
Vpr. VprL64P was expressed either alone or together with the wild
type Vpr by transfection of 293 cells. The amount of the plasmids
used was as indicated on top of the ¢gure. Two days after transfec-
tion, small molecular weight cellular DNA was prepared and ana-
lyzed. TAA: transfection with the pFSZ3-TAA plasmid which car-
ries a premature codon at Vpr amino acid #5 [25]. Lower panel:
Western blot with the Vpr polyclonal antibody [25]. C: Quanti¢ca-
tion of the DNA ladders in B. Value for lane 1 was deducted from
other lanes as the background. Net value for lane 2 (the wild type
Vpr) was normalized to 1. Numbers in parentheses indicate the
amount of DNA (Wg) used for transfection.
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the wild type Vpr on the pro-apoptotic activity of VprL64P
by co-expression of both proteins. Surprisingly, the wild type
Vpr inhibited apoptosis induction by VprL64P in a dose-
dependent manner (Fig. 1B, compare lanes 7^9 with lanes
4^6). With equal amounts of DNAs used for expression of
the wild type Vpr and VprL64P, apoptosis induced by
VprL64P was almost completely abolished (compare lane 9
with lane 6). Western blot suggested that the total level
of the wild type Vpr and VprL64P was higher when
VprL64P-induced apoptosis was inhibited (Fig. 1B, lane 9,
lower panel).
3.2. The VprL64P protein level is reduced in the presence of the
wild type Vpr
In the above Western blot analysis, the wild type Vpr and
VprL64P could not be distinguished. Thus, we engineered a
Flag epitope tag to the N-terminus of the wild type Vpr and
VprL64P, so that the Flag-tagged Vpr proteins and their un-
tagged counterparts can be distinguished during Western blot
analysis. The Vpr with double mutations, I61A/L64P, which
has approximately 20% of the pro-apoptotic activity of
VprL64P [25], was also modi¢ed to have a Flag tag as a
control. To examine the pro-apoptotic activities of the Flag-
tagged Vpr proteins, total cellular DNA, which includes DNA
from both apoptotic and non-apoptotic cells, was isolated
after DNA transfection, and analyzed for the existence of a
DNA ladder. As shown in Fig. 2A, F-VprL64P (lane 5) had a
reduced apoptotic potential compared to the untagged coun-
terpart VprL64P (lane 3), but remained much more pro-apo-
ptotic than F-Vpr (lane 4). F-I61A/L64P (Fig. 2A, lane 6) had
a pro-apoptotic activity similar to that of F-Vpr (lane 4).
Western blot with the Flag antibody showed that all Flag-
tagged Vpr proteins were expressed as expected (Fig. 2A,
bottom panel).
To examine whether Vpr can a¡ect the level of the
VprL64P mutant protein, the wild type Vpr was co-expressed
with F-Vpr, F-VprL64P, and F-I61A/L64P, and cell lysates
were examined by Western blot with the rabbit polyclonal
antibodies to Vpr (Fig. 2B). Co-expression of the wild type
Vpr with F-Vpr resulted in F-Vpr being expressed at a slightly
lower level than Vpr (Fig. 2B, lane 1), possibly due to com-
petition during protein synthesis. In contrast, co-expression of
Vpr with F-VprL64P (lane 2) and F-I61A/L64P (lane 3) ren-
dered the Flag-tagged Vpr mutant proteins to be produced at
an extremely low level. To examine if VprL64P also a¡ected
the levels of the Flag-tagged Vpr proteins, VprL64P was co-
expressed with these proteins and cell lysates examined the
same way (Fig. 2B, lanes 4^6). As shown, in the presence of
F-Vpr, VprL64P protein was almost abolished (Fig. 2B, lane
4). However, VprL64P was co-expressed well together with F-
VprL64P (Fig. 2B, lane 5) and F-I61A/L64P (lane 6),
although both Flag-tagged proteins were expressed at a
slightly lower level than VprL64P. These results suggest that
the wild type Vpr is capable of reducing the protein level of
L64P-containing Vpr mutants.
To examine if Vpr-induced decrease in the level of the
L64P-bearing mutants can occur in di¡erent cell types, we
used HeLa cells to express the Flag-tagged VprW54A/L64P
or VprL64P mutant either alone or together with the wild
type Vpr. As shown in Fig. 2C, expression of the mutant
proteins was extremely poor, rendering the e¡ect of the wild
type Vpr di⁄cult to discern.
Fig. 2. Protein level of L64P-containing Vpr mutants is reduced in
the presence of the wild type Vpr. A: Expression and pro-apoptotic
activities of N-terminally Flag-tagged Vpr and mutants. All proteins
were expressed in 293 cells by transfection. Two days after transfec-
tion, total cellular DNA, including DNA from both apoptotic and
normal cells, was prepared and analyzed. Lower panel: Western
blot with the Flag monoclonal antibody. B: Protein levels of the
VprL64P and I61A/L64P mutants are reduced in the presence of the
wild type Vpr. Expression constructs for the Flag-tagged Vpr and
untagged counterparts were co-transfected in combinations as indi-
cated. Flag-tagged proteins are labeled on top of the ¢gure and un-
tagged proteins are labeled on the bottom of the ¢gure. Two days
after transfection, cells were lysed and examined by Western blot
analysis with the Vpr polyclonal antibody. N.S.: non-speci¢c band.
C: L64P-bearing mutants of Vpr are expressed poorly in HeLa cells.
F-W54P/L64P and F-L64P mutants were expressed in HeLa cells ei-
ther alone or together with the wild type Vpr. Cell lysates were ex-
amined by Western blot as in B.
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3.3. Ability to reduce the protein level of Vpr mutants is shared
by Vpr molecules from di¡erent subtypes of HIV-1 and is
independent of apoptosis
The observation that protein level of the F-I61A/L64P mu-
tant was reduced by the wild type Vpr (Fig. 2B, lane 3) sug-
gested that the observed e¡ect was independent of apoptosis.
To examine this point further, we constructed additional Vpr
mutants carrying another single point mutation in addition to
L64P. As shown in Fig. 3A, both the L22A/L64P (lane 4) and
the E29A/L64P (lane 5) mutants were as e⁄cient as VprL64P
(lane 3) in induction of apoptosis. However, the pro-apoptotic
activity of the W54A/L64P mutant was abolished (lane 6).
These mutants were then co-expressed with the Flag-tagged
wild type Vpr, F-Vpr, and examined for their pro-apoptotic
activity by DNA analysis. Vpr proteins were examined by
Western blot with the Vpr anti-serum. As shown in Fig. 3B,
the pro-apoptotic activities of the three highly apoptotic Vpr
mutants were e¡ectively inhibited by F-Vpr (lanes 3^5). West-
ern blot (Fig. 3B, lower panel) showed that inhibition of ap-
optosis was correlated with a severe reduction in the protein
levels of the Vpr mutants. Interestingly, the W54A/L64P mu-
tant was negative in apoptotic activity, and yet its protein
level was also reduced by F-Vpr (Fig. 3B, lane 6). Thus, it
seemed that Vpr-induced reduction in the protein levels of
L64P-containing mutants is independent of the pro-apoptotic
activity of the mutants.
We previously reported that Vpr molecules from di¡erent
HIV-1 subtypes have di¡erent pro-apoptotic potentials possi-
bly due to sequence variations [25]. The Vpr molecule used for
most experiments in this study is from a subtype B HIV-1
isolate [25]. Importantly, a subtype D Vpr (rD) has no detect-
able pro-apoptotic activity but acquires the same level of pro-
apoptotic potential as VprL64P after substitution of Leu64
with a Pro residue [25]. In contrast, a subtype A/G hybrid
Vpr (rAG) has a low level of pro-apoptotic activity that can-
not be enhanced by the L64P mutation [25]. To examine if the
Vpr molecules of di¡erent subtypes of HIV-1 can all reduce
the protein level of L64P-containing mutants, the Flag-tagged
Vpr double mutant, F-W54A/L64P, was co-expressed with its
untagged counterpart W54A/L64P (Fig. 3C, lane 2), Vpr (lane
3), rD (lane 4), or rAG (lane 5). The results showed that the
Vpr molecules from the three di¡erent HIV-1 subtypes all
reduced the protein level of F-W54A/L64P despite their sig-
ni¢cant sequence variations [25].
3.4. Vpr-induced reduction in the protein level of L64P-
containing mutants is not due to changes in mRNA level
Next, we examined if Vpr-mediated protein inhibition was
exerted at the mRNA level. Since the vector and promoter
used for expression of both the wild type Vpr and all of the
C
Fig. 3. Ability to reduce the protein levels of L64P-containing Vpr
mutants is shared by Vpr molecules from di¡erent subtypes of HIV-
1 and is independent of apoptosis. A: Apoptosis induction by
L64P-containing Vpr mutants. Expression constructs were trans-
fected alone. Untagged proteins are indicated on top of the ¢gure.
Other conditions were the same as in Fig. 1B. B: Inhibition of
L64P-containing Vpr mutants by the wild type Vpr. Flag-tagged
wild type Vpr was co-expressed with untagged wild type Vpr or its
mutants (as indicated on top of the ¢gure). Other conditions were
the same as in A. C: Protein level of F-W54A/L64P is reduced in
the presence of Vpr molecules from di¡erent HIV-1 subtypes. West-
ern blot conditions were the same as in A. Expression and sequence
properties of the di¡erent Vpr molecules have been described previ-
ously [25]. Untagged Vpr proteins are indicated on bottom of the
¢gure. rD and rAG are Vpr molecules from a subtype D and a sub-
type A/G recombinant HIV-1, respectively.
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Vpr mutants were the same, preferential e¡ects of the wild
type Vpr on the mRNA level of the L64P-containing mutants
were considered unlikely. To con¢rm this, F-Vpr and W54A/
L64P were co-expressed by DNA co-transfection, and the rel-
ative mRNA levels of F-Vpr and W54A/L64P were analyzed
by RT-PCR. As a control, F-Vpr was also co-expressed with
the VprW54A mutant, which was not a¡ected by co-expres-
sion of the wild type Vpr. Two RT-PCR primers were de-
signed to simultaneously amplify both the F-Vpr mRNA
and the W54A/L64P mRNA (Fig. 4A), resulting in two
DNA fragments separable on polyacrylamide gels. The RT-
PCR product from F-Vpr mRNA was longer due to the in-
sertion of the Flag epitope-coding sequence (Fig. 4A). During
the PCR step, the template (RT reaction product) was serially
diluted so that some of the PCR reactions would not progress
to saturation.
Cell samples used for RT-PCR analysis were ¢rst examined
for Vpr expression by Western blot. As shown in Fig. 4B,
control analysis of VprW54A showed that VprW54A was
not signi¢cantly inhibited by co-expression of F-Vpr (Fig.
4B, compare lane 1 with lane 3). In contrast, W54A/L64P
expression was undetectable in the presence of F-Vpr (Fig.
4B, lane 4), and normal in the absence of F-Vpr (lane 2).
Cell samples corresponding to lanes 3 and 4 of Fig. 4B were
subjected to RT-PCR analysis. This analysis revealed that the
mRNA level of W54A/L64P (Fig. 4C, lower band in lanes
6^8) was similar to the mRNA levels for F-Vpr (upper band
in lanes 2^4 and 6^8) and VprW54A (lower band in lanes
2^4). When the RT reaction was carried out in the absence
of the reverse transcriptase enzyme (Fig. 4C, lanes 1 and 5),
the PCR reaction did not yield any product, suggesting that
the observed PCR signals were all from the speci¢c mRNA
molecules. Thus, inhibition of the W54A/L64P protein by F-
Vpr was not due to a potential suppression of the mRNA for
the W54A/L64P mutant protein.
3.5. Turnover of the VprW54A/L64P mutant protein is
enhanced by the wild type Vpr
To examine if Vpr-mediated inhibition of L64P-containing
mutants was correlated with a more marked turnover of the
mutants, F-W54A/L64P was co-expressed with its untagged
counterpart W54A/L64P (Fig. 4E, lanes 1^4, upper panel),
or the wild type Vpr (lower panel). Transfected cells were
labeled with [35S]methionine, and then washed and incubated
with regular medium for di¡erent lengths of time before lysis
for examination of the F-W54A/L64P protein. All cell lysates
Fig. 4. Vpr-induced reduction in the protein level of the W54A/L64P mutant is correlated with a faster rate of turnover and not with changes
in the mRNA level. A: Illustration of Vpr expression constructs used for co-transfection. Arrows indicate transcriptional start sites. Bars in-
dicate positions of the primers (p3 and p4) for RT-PCR. Primer sequences are listed in Section 2. B: Inhibition of VprW54A/L64P, but not
VprW54A, by the Flag-tagged wild type Vpr. VprW54A and the W54A/L64P mutant (as indicated on the bottom of the ¢gure) were either
expressed alone (lanes 1 and 2), or co-expressed with F-Vpr (lanes 3 and 4). Western blot was performed with the Vpr polyclonal antibody.
C: RT-PCR analysis of cell samples corresponding to lanes 3 and 4 of B. RT-PCR products were examined as described in Section 2. ‘Start-
ing’: starting dilution of the RT reaction product used for the subsequent PCR reactions. ‘RT3’ : RT enzyme was omitted during RT reaction.
Fþ and F3 : RT-PCR DNA product from F-Vpr mRNA and the untagged Vpr mutants (as indicated on the bottom of the ¢gure), respec-
tively. M: 100-bp ladder marker (Promega). D: Quanti¢cation of data in C. Methods were the same as in Fig. 1C. Numbers in parentheses
correspond to the lane number of B. E: Turnover rate of the F-W54A/L64P mutant protein is enhanced by the wild type Vpr. F-W54A/L64P
was co-expressed with its untagged counterpart (lanes 1^4, upper panel) or with the wild type Vpr (lanes 1^4, lower panel). Cells were subjected
to pulse-chase labeling as described in Section 2, and F-W54A/L64P examined by immunoprecipitation, SDS^PAGE, and phosphor-image anal-
ysis. Lane 5: control transfection with the Vpr-null construct pFSZ3-TAA. The control lane 5 has a non-speci¢c band at a slightly lower posi-
tion than F-W54A/L64P. F: Quanti¢cation of F-W54A/L64P. For both sets of samples, the signal intensity at the beginning of the chase was
normalized to 100.
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were immunoprecipitated with the Flag antibody and the im-
munoprecipitates were examined by SDS^PAGE, followed by
phosphor-image analysis. As shown in Fig. 4E,F, the rate of
F-W54A/L64P turnover was much faster in the presence of
the wild type Vpr than in its absence. Thus, Vpr-induced
reduction in the protein level of L64P-containing mutants
appears to be correlated with a faster turnover rate of the
mutant proteins.
3.6. The wild type Vpr facilitates ubiquitination of the
VprW54A/L64P mutant protein
Degradation of many cellular proteins is mediated by the
ubiquitin/proteasome pathway [27]. To examine if Vpr-pro-
moted turnover of the W54A/L64P mutant protein was
through the proteasome pathway, we expressed F-W54A/
L64P either alone or together with the wild type Vpr. Two
days after transfection, cells were labeled with [35S]methionine
and then treated with the proteasome inhibitor MG132. The
level of the F-W54A/L64P mutant protein was examined by
radio-immunoprecipitation. As shown in Fig. 5A, treatment
of cells with MG132 increased the level of F-W54A/L64P in
the absence and in the presence of the wild type Vpr. How-
ever, the extent of MG132-induced increase in F-W54A/L64P
was most striking in the presence of the wild type Vpr (Fig.
5A, lanes 4 and 5).
To examine if the observed e¡ect of MG132 was correlated
with enhanced ubiquitination of the VprW54A/L64P mutant,
we co-expressed the F-W54A/L64P mutant protein with the
wild type Vpr as well as with HA-tagged ubiquitin. The trans-
fected cells were treated with MG132 and analyzed for F-
W54A/L64P and HA-ubiquitin by immunoprecipitation with
the Flag antibody followed by Western blots. As shown in
Fig. 5B, expression of F-W54A/L64P alone generated a low
level of poly-ubiquitinated F-W54A/L64P (lane 2, upper pan-
el). In contrast, co-expression of F-W54A/L64P with the wild
type Vpr generated a much higher level of poly-ubiquitinated
F-W54A/L64P (Fig. 5B, lane 3, upper panel), despite the fact
that F-W54A/L64P was detected at a much lower level in the
presence of the wild type Vpr than in its absence (Fig. 5B,
lower panel). These results suggest that the wild type Vpr
enhances the ubiquitination of F-W54A/L64P and its subse-
quent degradation through the proteasome pathway.
We previously demonstrated that Vpr puri¢ed from bacte-
ria exists as an oligomer [30]. One hypothesis for Vpr-pro-
moted ubiquitination/degradation of the VprW54A/L64P mu-
tant is that the wild type Vpr forms a complex with the
mutant protein due to their tendency to form oligomers. To
examine if Vpr in mammalian cells also exists as an oligomer,
transfected 293 cells were cross-linked with DSS in vivo, and
Vpr was detected by Western blot. As shown in Fig. 5C, DSS
treatment induced a higher molecular weight form of the wild
type Vpr, which was consistent with a Vpr dimer (lane 3). The
Flag-tagged Vpr (Fig. 5C, lane 5) was also cross-linked into
an apparent dimer of a higher molecular weight than the
untagged Vpr dimer (lane 3). Interestingly, when Vpr and
F-Vpr were co-expressed, an apparent Vpr/F-Vpr heterodimer
was detected (Fig. 5C, lane 4). These results showed that the
wild type Vpr forms a dimer in vivo. Similar analysis of the
VprW54A/L64P mutant also revealed a dimer of the mutant
protein (data not shown). However, co-expression of the wild
type Vpr with the VprW54A/L64P mutant failed to reveal a
heterodimer of these proteins (see Section 4).
Fig. 5. Vpr forms a dimer in vivo and promotes ubiquitination of
the VprW54A/L64P mutant protein. A: Proteasome inhibitor
MG132 enhances the protein level of F-W54A/L64P in the presence
and absence of the wild type Vpr. F-W54A/L64P was expressed ei-
ther alone (lanes 2 and 3) or in the presence of the wild type Vpr
(lanes 4 and 5). Cells were labeled with [35S]methionine, and either
treated or not treated with MG132 as indicated. Cell lysates were
immunoprecipitated with the Flag antibody and analyzed as de-
scribed in Fig. 4E. B: The wild type Vpr enhances ubiquitination of
F-W54A/L64P. HA-tagged ubiquitin (HA-Ub) was co-expressed
with F-W54A/L64P (lane 2) or F-W54A/L64P together with the
wild type Vpr (lane 3). Cells were treated with MG132 and cell ly-
sates immunoprecipitated with the Flag antibody. The immunopreci-
pitates were examined by Western blot with the HA antibody
(upper panel) or the Flag antibody (lower panel). Positions of the
poly-ubiquitinated F-W54A/L64P are indicated. C: Vpr forms a
dimer in vivo. 293 cells expressing Vpr (lane 3), F-Vpr (lane 5) or
both proteins together (lane 4) were cross-linked with DSS and ex-
amined by Western blot with the Vpr antibodies. ‘Vpr/F-Vpr’ indi-
cates the heterodimer between Vpr and F-Vpr. N.S.: non-speci¢c
band.
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3.7. Inhibition of proteasome-mediated degradation strongly
enhances the cytoplasmic fraction of the VprW54A/L64P
mutant
Since protein ubiquitination can occur both in the cyto-
plasm and in the nucleus, we ¢rst examined if the L64P mu-
tation a¡ects the subcellular distribution of Vpr. 293 cells
expressing either the wild type Vpr or the VprL64P mutant
were fractionated into cytoplasmic and nuclear fractions and
Vpr expression examined by Western blot. By this analysis,
the wild type Vpr (Fig. 6A, lanes 1 and 2) and the VprL64P
mutant (lanes 3 and 4) were shown to have a similar pattern
of distribution with a higher amount of the Vpr proteins
found in the nuclear fraction. Analysis of the nuclear protein,
poly-ADP-ribosyl polymerase, and the cytoplasmic protein
actin revealed their predominant nuclear and cytoplasmic lo-
calization, respectively.
To examine the potential e¡ect of proteasome inhibitor
MG132 on the subcellular localization of Flag-tagged
VprW54A/L64P mutant in the presence and absence of the
wild type Vpr, transfected cells were metabolically labeled
with [35S]methionine, treated with MG132, and then incuba-
ted in regular medium for 40 min to allow newly synthesized
proteins to enter the nucleus. Cells were fractionated and
presence of F-W54A/L64P in the cytoplasmic and nuclear
fractions examined by radio-immunoprecipitation. As shown
in Fig. 6B, in the absence of MG132, F-W54A/L64P assumed
a similar nuclear/cytoplasmic distribution pattern (lanes 7 and
8) as the wild type F-Vpr (lanes 3 and 4). MG132 treatment
did not a¡ect either the distribution or the expression level of
F-Vpr (Fig. 6B, lanes 5 and 6). In contrast, MG132 treatment
signi¢cantly increased the amount of F-W54A/L64P in the
cytoplasmic fraction both in the absence (Fig. 6B, lane 9)
and in the presence (lane 13) of the wild type Vpr. Thus,
ubiquitination/degradation of the VprW54A/L64P mutant ap-
pears to be predominantly in the cytoplasm.
4. Discussion
Vpr remains to be one of the major puzzles of HIV-1 rep-
lication and pathogenesis. While it is non-essential for viral
replication in vitro, the Vpr gene is highly conserved among
various subtypes of HIV-1. In addition, the many interesting
biological activities of Vpr, such as pro-apoptosis and cell
cycle arrest, render it possible for Vpr to exert signi¢cant
e¡ects during HIV-1 replication and pathogenesis in vivo.
Despite this, the biochemical mechanism of Vpr function re-
mains unclear. While it is logical to propose that Vpr has
multiple functions with di¡erent biochemical mechanisms, it
is also critical to consider the hypothesis that Vpr has a major
function with a speci¢c biochemical mechanism that facilitates
HIV-1 replication and pathogenesis in vivo.
The novel observation in this article is that the wild type
Vpr promotes ubiquitination/degradation of the L64P-bearing
Vpr mutants. This e¡ect is speci¢c and uni-directional : the
mutant protein does not a¡ect the stability of the wild type
Vpr, suggesting a dominant activity of the wild type Vpr. It is
interesting to note that the likelihood of the wild type Vpr to
co-exist with the mutant Vpr in vivo is low. Most importantly,
however, our unique experimental system has allowed the
detection of this novel activity of Vpr and the generation of
experimental results that strongly suggest an interaction be-
tween the wild type Vpr and the cellular ubiquitination path-
way.
Beyond its traditional role in protein degradation, protein
ubiquitination has recently been shown to be an important
player in a variety of cellular processes, including transcrip-
tion, endocytosis, cell cycle, and apoptosis [31]. This impor-
tant advance is made possible by the biochemical and struc-
tural characterization of the major factors involved in
ubiquitination, including E1 (ubiquitin-activating enzyme),
E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase)
[32,33]. ‘Adapter’ molecules in conjunction with the E3 en-
zyme are responsible for recruiting speci¢c protein substrates
for regulated ubiquitination [34]. Protein substrates may be
also post-translationally modi¢ed, such as phosphorylated,
to provide a signal for recognition by the ubiquitination en-
zyme complex.
Since the wild type Vpr promotes the ubiquitination of the
VprW54A/L64P mutant, it may be hypothesized that Vpr si-
multaneously interacts with the Vpr mutant protein and a
cellular factor involved in protein ubiquitination. Similarly,
the wild type Vpr may form a ternary complex with the Vpr
mutant protein and an unknown cellular factor, enhancing the
post-translational modi¢cation of the mutant Vpr protein.
The post-translationally modi¢ed mutant Vpr protein may
Fig. 6. MG132 treatment enhances the cytoplasmic fraction of the
VprW54A/L64P mutant in the presence and absence of the wild
type Vpr. A: Subcellular distribution of Vpr and VprL64P. Cyto-
plasmic (C) and nuclear (N) fractions of 293 cells transfected with
the indicated expression constructs were examined by Western blot
with antibodies to Vpr (top panel), poly-ADP-ribosyl polymerase
(PARP, middle panel), and actin (bottom panel). N.S.: non-speci¢c
band. B: MG132 treatment enhances the cytoplasmic fraction of the
VprW54A/L64P mutant. Cytoplasmic and nuclear fractions of ra-
diolabeled cells were examined by immunoprecipitation followed by
phosphor-image analysis. Treatment with MG132, as indicated on
the bottom of the panel, is described in Section 2. The expressed
Vpr proteins were labeled on the top of the ¢gure. Arrow indicates
the position of the Flag-tagged Vpr proteins.
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be more susceptible to ubiquitination and degradation
through the proteasome pathway. Biochemical studies of
Vpr suggest that Vpr is capable of forming oligomers in vitro
[30] and dimers in vivo (Fig. 5C). By a similar analysis, the
VprW54A/L64P mutant also formed a dimer in vivo, and yet
a heterodimer between the wild type Vpr and the VprW54A/
L64P mutant could not be detected (data not shown). The
failure to observe a complex between the wild type Vpr and
the mutant Vpr may be due to several reasons. First, the
protein level of the mutant Vpr is extremely low in the pres-
ence of the wild type Vpr, rendering the analysis of the po-
tential complex di⁄cult. Second, the complex could be unsta-
ble. This would be consistent with the observation that only
the mutant protein and not the wild type protein is ubiquiti-
nated and degraded.
This model of Vpr function also suggests the possibility that
a cellular factor may be destabilized in the presence of Vpr by
direct interaction with Vpr. This cellular factor may be inhib-
itory to HIV-1 replication under physiological conditions but
may be di⁄cult to identify due to its degradation enhanced by
Vpr. This potential mode of Vpr function is similar to the
mechanism of function of HIV-1 auxiliary regulatory proteins
Vif and Vpu. Vif has been shown to interact with and pro-
motes the degradation of the cellular cytidine deaminase,
CEM15/APOBEC3G which is expressed only in non-permis-
sive cell lines and inactivates the HIV-1 genome by intro-
ducing multiple mutations during the process of reverse tran-
scription [35,36]. Vif-mediated degradation of CEM15/
APOBEC3G has also been shown recently to be through
the ubiquitin/proteasome pathway [37^42]. Vpu has been
shown to interact simultaneously with CD4 and L-TrCP
[43]. L-TrCP is responsible for the recruitment of the Vpu^
CD4 complex to the E3 ubiquitin ligase complex for ubiquiti-
nation and degradation [43].
Pro mutations are expected to disrupt protein helical struc-
tures. To gain a better view of the L64P-induced thermody-
namic changes in Vpr helix III, free-energy calculation of
VprL64P mutant was carried out using Swiss-pdbViewer
and the recent Vpr structural data acquired by NMR studies
[29]. L64P mutation would increase the free energy of Vpr
structure from (3)3853 kJ/mol to (+)2297 kJ/mol. Free-energy
penalties result mostly from the existence of un-bonded side
chains of Leu60, Ile61, and Pro64. Thus, helix III would be
disrupted from residue Leu60 to residue L64P. It has recently
been shown that Vpr interacts with cyclophilin A (cypA) and
this interaction is critical for the functional expression of Vpr
[44]. CypA speci¢cally targets the Pro35 residue of Vpr and
exerts its e¡ects during the translation of Vpr. As suggested,
structural modi¢cations of Vpr by cypA are critical for the
biological activity of Vpr. It is possible that cypA-induced
modi¢cations of Vpr mutants bearing the L64P mutation
also a¡ect the interaction between these Vpr molecules and
the cellular protein ubiquitination pathway.
Despite the structural changes induced by the L64P muta-
tion, the subcellular distribution of the L64P-bearing Vpr mu-
tants appears to be similar to that of the wild type Vpr (Fig.
6). This is consistent with the observation that Vpr has two
independent domains for nuclear transport [45^47]. The
VprL64P and W54A/L64P mutants were also incorporated
normally into HIV-1 virion-like particles (data not shown).
By radiolabeling of cells followed by fractionation, the sub-
cellular distribution of the VprW54A/L64P mutant appeared
to be similar in the absence and presence of the wild type Vpr
(Fig. 6B). However, while MG132 treatment did not a¡ect the
expression or localization of the wild type Vpr, it signi¢cantly
enhanced the cytoplasmic fraction of the VprW54A/L64P mu-
tant (Fig. 6B). Since MG132 inhibits proteasome degradation
and not ubiquitination, these results suggest the interesting
possibility that the VprW54A/L64P mutant is ubiquitinated
in the cytoplasm and ubiquitination retards its nuclear migra-
tion. Since the wild type Vpr promotes ubiquitination and
degradation of the VprW54A/L64P mutant, it seems possible
that the wild type Vpr may target a ubiquitination/proteasome
pathway in the cytoplasm.
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